Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million)EBITDA for the Group reache ...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros booth and featured in ...

Core Viewpoint - Kuros Biosciences is currently investigating the resignation of former Board member Albert Arp, who allegedly resigned due to sharing price-sensitive information with a third party, but the company asserts this matter does not affect its strategic direction or financial performance [1]. Company Overview - Kuros Biosciences is focused on innovative biologic technologies and is listed on the SIX Swiss Exchange, with operations in the United States, Switzerland, and the Netherlands [5]. - The company's flagship product, MagnetOs, is an advanced bone graft used globally across four continents [5]. Product Information - MagnetOs has demonstrated a fusion rate of 79% in a Level I clinical study, nearly double that of autograft at 47% for posterolateral fusions [3]. - Among active smokers, the fusion rate difference was even more pronounced, although specific data for this subgroup was not statistically analyzed [3][7]. - MagnetOs utilizes NeedleGrip technology to stimulate bone growth without added cells or growth factors, and it is FDA cleared for use throughout the spine [3]. Regulatory and Usage Notes - MagnetOs is not cleared as an osteoinductive bone graft and must be used with an FDA-cleared intervertebral body fusion device [8].

Company Overview - Kuros Biosciences is a leader in next-generation bone healing technologies, with a mission to discover, develop, and deliver innovative biologic technologies [2][7] - The company is listed on the SIX Swiss Exchange and has locations in the United States, Switzerland, and the Netherlands [7] Board of Directors Changes - Albert Arp has resigned from the Board of Directors for personal and professional reasons, effective immediately [2] - Oliver Walker has been appointed as Chair of the Audit and Risk Committee [2] - Kimberley Elting has been appointed as a member of the Audit and Risk Committee and as Chair of the Compensation and Nomination Committee [2] Product Information - Kuros's first commercial product, MagnetOs, is an advanced bone graft that has been used across four continents [7] - In a Level I human clinical study, MagnetOs achieved a fusion rate of 79%, nearly double that of autograft at 47% in posterolateral fusions [5] - Among active smokers, the fusion difference was even more pronounced, although specific data for this subgroup was not statistically analyzed [5][9] - MagnetOs utilizes NeedleGrip technology to stimulate bone growth without added cells or growth factors, and it is FDA cleared for use throughout the spine [5]

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ("Kuros" or the "Company") a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached U ...

Core Insights - Kuros Biosciences is set to present its latest developments regarding MagnetOs and its strategic priorities during the Capital Markets Day on May 13, 2025, in Zürich, Switzerland [1][2] Company Overview - Kuros Biosciences is a leader in innovative biologic technologies, focusing on bone healing solutions [1][9] - The company is expanding its global footprint and targeting both spinal and extremity markets, with anticipated growth in the U.S., Europe, and other regions [6] Product Insights - MagnetOs is a proprietary bone healing technology that has shown nearly double the fusion rate compared to autograft in a Level I human clinical study, particularly effective among active smokers [6][7] - The technology utilizes NeedleGrip™, a submicron surface technology that stimulates bone growth without added cells or growth factors [6][7] Strategic Priorities - Kuros aims to improve patient outcomes and drive shareholder value through innovation, strategic partnerships, and global growth [4][6] - The company is leveraging its alliance with Medtronic to enhance market access and accelerate product adoption [6] Clinical Insights - Seven Level I human clinical trials are currently underway to demonstrate MagnetOs' efficacy in promoting bone growth and fusion across various surgical applications [6] - Insights from Dr. Greg Berlet, a leading orthopedic surgeon, will be shared, highlighting the advantages of MagnetOs from both surgeon and patient perspectives [2][6]